These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

911 related items for PubMed ID: 29129436

  • 1. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
    Lancet; 2018 Jan 20; 391(10117):230-240. PubMed ID: 29129436
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial.
    Body JJ, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P.
    Osteoporos Int; 2020 Oct 20; 31(10):1935-1942. PubMed ID: 32474650
    [Abstract] [Full Text] [Related]

  • 3. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS, LOFT Investigators.
    Lancet Diabetes Endocrinol; 2019 Dec 20; 7(12):899-911. PubMed ID: 31676222
    [Abstract] [Full Text] [Related]

  • 4. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
    Minisola S, Marin F, Kendler DL, Geusens P, Zerbini CAF, Russo LA, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Moericke R, Bagur A, Lakatos P, López-Romero P, Body JJ.
    Arch Osteoporos; 2019 Jan 18; 14(1):10. PubMed ID: 30659410
    [Abstract] [Full Text] [Related]

  • 5. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.
    Osteoporos Int; 2012 Aug 18; 23(8):2141-50. PubMed ID: 22159672
    [Abstract] [Full Text] [Related]

  • 6. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators.
    JAMA; 2016 Aug 16; 316(7):722-33. PubMed ID: 27533157
    [Abstract] [Full Text] [Related]

  • 7. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
    Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF.
    Lancet Diabetes Endocrinol; 2018 Jun 16; 6(6):445-454. PubMed ID: 29631782
    [Abstract] [Full Text] [Related]

  • 8. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
    Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body JJ, Minisola S.
    Bone; 2020 Jan 16; 130():115113. PubMed ID: 31654779
    [Abstract] [Full Text] [Related]

  • 9. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.
    Geusens P, Kendler DL, Fahrleitner-Pammer A, López-Romero P, Marin F.
    Calcif Tissue Int; 2020 Jun 16; 106(6):646-654. PubMed ID: 32157334
    [Abstract] [Full Text] [Related]

  • 10. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Nov 16; 26(11):2677-84. PubMed ID: 26092063
    [Abstract] [Full Text] [Related]

  • 11. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.
    JAMA; 1999 Oct 13; 282(14):1344-52. PubMed ID: 10527181
    [Abstract] [Full Text] [Related]

  • 12. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR.
    Osteoporos Int; 2009 Dec 13; 20(12):2095-104. PubMed ID: 19350340
    [Abstract] [Full Text] [Related]

  • 13. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA.
    Lancet; 2015 Sep 19; 386(9999):1147-55. PubMed ID: 26144908
    [Abstract] [Full Text] [Related]

  • 14. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep 19; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 15. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
    Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, López-Romero P, Fahrleitner-Pammer A.
    J Bone Miner Res; 2018 May 19; 33(5):783-794. PubMed ID: 29329484
    [Abstract] [Full Text] [Related]

  • 16. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
    Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.
    Osteoporos Int; 2012 Jan 19; 23(1):277-84. PubMed ID: 21365461
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR, Lee J.
    Osteoporos Int; 2019 Mar 19; 30(3):659-666. PubMed ID: 30535785
    [Abstract] [Full Text] [Related]

  • 18. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH.
    J Bone Joint Surg Am; 2009 Jun 19; 91(6):1329-38. PubMed ID: 19487509
    [Abstract] [Full Text] [Related]

  • 19. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov 19; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
    Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S.
    Osteoporos Int; 2021 Nov 19; 32(11):2301-2311. PubMed ID: 34002252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.